NCT05883072 Exploring the Effectiveness of AI Generative Models for Diabetic Patients
| NCT ID | NCT05883072 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pakistan Council of Scientific and Industrial Research |
| Condition | Diabetes Mellitus, Type 2 |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2023-01-05 |
| Primary Completion | 2024-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2023-01-05 with a primary completion date of 2024-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
We plan to explore the usability of Generative AI-Chatbot for Diabetic Patient
Eligibility Criteria
Inclusion Criteria: * Present physically in Pakistan * Adults (18 years or older) * Diabetic Patient Exclusion Criteria: * Adults unable to consent * Individuals who are not yet adults (infants, children, teenagers) * Prisoners
Contact & Investigator
Ghulam Mustafa
PRINCIPAL INVESTIGATOR
Pakistan Council of Scientific and Industrial Research
Frequently Asked Questions
Who can join the NCT05883072 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Diabetes Mellitus, Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05883072 currently recruiting?
Yes, NCT05883072 is actively recruiting participants. Contact the research team at mustafabme@gmail.com for enrollment information.
Where is the NCT05883072 trial being conducted?
This trial is being conducted at Karachi, Pakistan.
Who is sponsoring the NCT05883072 clinical trial?
NCT05883072 is sponsored by Pakistan Council of Scientific and Industrial Research. The principal investigator is Ghulam Mustafa at Pakistan Council of Scientific and Industrial Research. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.